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Pati~nts with atopic dermatitis (AD) have elevated leukocyte 
cychc AMP-phosphodiesterase (PDE) activity and increased 
111 Vitro IgE synth esis compared to normal (NL) subjects. 
Int~rleukin 4 (IL-4), interferon-gamma (IFN-y), and PDE 
I11h.'b'tor have been shown to regulate in vitro IgE synthesis. 
This study investigated whether soluble T -cell factors such as 
IL-4 and IFN-y could account for elevated PDE activity in 
patients with AD. 
Both rhIL-4 and IFN-y significantly increased normal 
monocyte PDE activity to a maximum of 188% (n = 6, P < 
0: 05) and 315% above control (n = 3, P < 0.05), respec-
tively. At concentrations below 0.1 units/ml IL-4 and IFN-y 
had synergistic effects on activation of monocyte PDE. AD fnd NL T-cell culture supernatants also significantly stimu-
ated normal monocyte PDE activity, but the stimulatory 
A topic dermatitis (AD) is a chronically recurrent cutane-ous inflammatory disease characterized by a variety of immunologic and pharmacologic abnormalities, in-cluding elevated basophil histamine release, increased I . spontaneous IgE production, and decreased intracellu-
ar cycliC AMP responses [1 - 3]. Our previous studies showed that 
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activity was not significantly greater in the AD T-cell super-
natants. The effect of both cytokines and T-cell supernatants 
on normal monocytes was inhibited by antibodies against 
IL-4 and IFN-y, respectively. 
This study demonstrates that IL-4 and IFN -I' can increase 
PDE activity in normal monocytes. Though the levels of 
IL-4 and IFN-y in T-cell supernatants are undetectable with 
an enzyme-linked immunosorbent assay (ELISA) assay, the 
concentration of these cytokines below the detectable level 
can significantly increase PDE activity of monocytes in a 
synergistic and dose-dependent manner. These results sug-
gest that cytokine-mediated activation of monocytes can in-
crease PDE activity. Furthermore, lymphokines may play an 
important role in modulating the cyclic nucleotide regula-
tory pathway. ] Invest Dermatol 99:65 - 70, 1992 
peripheral blood mononuclear cells (PBMe), particularly mono-
cytes, from patients with AD have elevated cAMP-phosphodiester-
ase (PDE) activity that accounts for the reduced cellular cAMP 
response [4 - 5]. PDE inhibitor treatment reduces histamine hyper-
releasibility and hyper-IgE production by atopic leukocytes in vitro 
[1,6]. The cause of elevated PDE activity in AD and its relationship 
to the over-production of IgE are not yet clear. 
Recent studies suggest that the T-cell cytokines interleukin 4 
(IL-4) and interferon-gamma (IFN-y) are important in regulating 
IgE production. Recombinant human IL-4 stimulates IgE produc-
tion by cultured human B cells in the presence of T cells and this 
effect can be modulated by the presence of monocytes and other 
cytokines [7 ,8]. Human IFN-y inhibits IL-4-induced IgE produc-
tion [8,9], and recent reports demonstrate that IL-4 can inhibit 
IFN-y expression and production in vitro [10 ,11]. IL-4 also has 
other effects, such as stimulating monocyte differentiation to macro-
phages [12], increasing the expression of class I and class II major 
histocompatibility complex cel l-surface antigens [13]' and decreas-
ing IL-l, IL-6 secretion [14,15]. 
We recently showed that T cells from patients with AD ex-
pressed higher levels of IL-4 mRNA, with or without stimulation, 
compared to normal T cells [16] , and this is suggested by studies 
showing increased numbers of IL-4-producing T-cell clones iso-
lated from the blood of atopic individuals [17,18]. Reinhold et al 
demonstrated that PBMC from patients with AD have reduced 
IFN-y production compared to PBMC from NL donors [19]. Other 
indirect evidence has suggested increased T-cell activation in AD 
[20]. 
We questioned whether dysregulation of cytokine production 
from activated AD T cells might relate to the elevated PDE activity 
in atopic monocytes. We assessed whether IL-4 and IFN-y have 
reciprocal effects on normal monocyte PDE activity. We also com-
pared the effects of NL and AD T-cell supernatants on normal 
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monocytes considering that these supernatants might contain IL-4 
and other products of T lymphocytes. 
MATERIALS AND METHODS 
Subjects Normal blood donors had no personal history of atopic 
disease and were on no medication at the time of the study. Patients 
with AD were chosen according to well-defined criteria [21); all 
were adult patients with chronic moderate to severe dermatitis. 
Both NL and AD donors had ingested no caffeine or other methyl 
xanthine-containing beverages for at least 12 h prior to morning 
blood drawing,. from heparinized venous blood. 
Monocyte Separation Peripheral blood mononuclear cells 
(PBMe) were separated by Ficoll-hypaque density gradient centrif-
ugation (Histopaque , Sigma Chemical Co., St. Louis, MO) [22). 
Briefly, PBMC recovered from the plasma/histopaque interface 
were washed three times with normal saline, resuspended in RPMI-
1640 with 15% heat-inactivated fetal calf serum (FCS) at 4 X 106 
cells/ml, and allowed to adhere in a 16 X 100 mm Petri dish (Fal-
con) for at least 90 min at 3re. The non-adherent cells were 
removed by decanting and washing thrice with 5 ml of warm Gey's 
balanced salt solution (GBSS, GmCO BRL Life T echnologies, Inc., 
Gaithersburg, MD). The adherent cells were recovered by scraping 
the dishes with a steril e rubber policeman. 
T-Cell Supernatants T cell s were separated from healthy non-
atopic and AD donors using a modified sheep RBC (sRBe) E-roset-
ting method [23) . More recently, T -cell recovery columns (Biotex 
Laboratories, Inc., Edmonton, Alberta, Canada) were used for T-
cell separation according to manufacturer's protocols. Briefly, non-
ad herent cells (at 1 to 1.5 X 108 cells/ml) were loaded onto the 
T-cell recovery column pre-coated with goat anti-human anti-sera. 
T cells were eluted by washing the column with 20 ml of phos-
phate-buffered saline (PBS) and the B cells were retained in the 
column. Purified T cells were resuspended in RPMI-1640 supple-
mented with 10% FCS: 1 % L-glutamine, 1 % streptomycin/peni-
cillin at 2 X 106 cells/ml and cultured at 3rc for 24 h in a 5% CO2 
95% moisture chamber. After culture, T-cell supernatants were 
harvested by pelleting cultured cells at 700 X g at 4 °C and filtering 
(millex-HA mini filter 0.45 .uM, Millipore Corp., Bedford, MA) . 
T he T-cell supernatants were then stored at -70°e. The T-cell 
supernatants used for monocyte stimulation were pooled using 
equal amounts from four individual supernatants from either nor-
mal or AD donors. No difference was found between T-cell super-
natants obtained from sRBC rosetting method - separated T cells 
and T-cell supernatants from T-cell column - separated T cells (data 
not shown). 
Cell Characterization Cell viability was monitored by trypan 
blue exclusion. The viability of PBMC, non-adherent cell, and T-
cell preparations were always greater than 98%, and the viability of 
adherent cell s (monocyte-rich) was greater than 90%. Cell differ-
entials were measured with Stat Stain (Volu-Sol Logos Scientific, 
Inc., Henderson, NV) . The PBMC contained approximately 10 to 
40% monocytes, 60 to 70% lymphocytes, 1 to 2% polymorphonu-
clear leukocytes and :s; 5% platelets. The non-adherent cells were 
typically ~95% lymphocytes. The adh erent cells were ~95% (X-
naphthylacetate es terase (ANAE, Sigma) and factor XIII-positive 
cells. T-cell preparations were 97% pure when immunoperoxidase 
stained with anti-CD3, and comprised 3 to 5% of adherent cell 
populations as determined by ANAE staining. 
IL-4 and IFN-y Levels in T-Cell Supernatants The quantita-
tive determination of human IL-4 and IFN-y were performed by 
enzyme-linked immunosorbent assay (ELISA) kits (Genzyme, Inc. , 
Boston, MA), according to manufacturer's protocols. Briefly, 96-
well microtiter plates were coated with a monoclonal mouse anti-
rhIL-4 or anti - rhIFN -y antibody for 48 h at 4 ° e. The plates were 
was hed with PBS four times and T-cell supernatants were then 
applied to the coated wells in duplicates and incubated for 120 min 
at room temperature. After washing the plates, polyclonal rabbit 
anti-human IL-4 or goat anti-human IFN-y were added and incu-
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
bated for 120 min at room temperature. Subsequently, the wells 
were washed again and incubated with a polyvalent, biotin-labeled 
goat anti-rabbit (IL-4) or donkey anti-goat (IFN -y) Ig for 45 min at 
room temperature. Finally, streptavidin-peroxidase was added and 
enzyme activity was determined with the peroxide substrate and 
O-phenylene diamine (OPD) chromagen. The plates were read 
with a Microplate Auto-Reader (Bio-T ek Instruments, Inc., Win-
ooski, VT). Standard curves were generated with serials dilution of 
highly purified rhIL-4 or rhIFN-y. The sensitivity of the assay was 
90 pg/ml (2.25 units/ml) for IL-4 and 100 pg/ml (2.5 units/ml) for 
IFN-y. 
IL-4 and IFN-y Human recombinant IL-4 was a generous gift 
from Dr. Y. P. Yung (Amgen, Thousand Oaks, CA; specific activity 
105 units/.ug). Anti-IL-4, an IgG class rabbit anti-human IL-4 po-
Iyclonal antibody, was purchased from Genzyme, Inc. (Boston, 
MA). At 0.25 .ug/ml, it totally inhibited bioactivity induced by 
1000 pg/ml of human IL-4. Both human recombinant IFN-y (spe-
cific activity 1.9 X 107 units/mg) and polyclonal rabbit anti-human 
IFN-y (3 X 105 neutralization units/ml) were kindly provided by 
Genentech, Inc. (South San Francisco, CA). All cytokines and anti-
bodies were dissolved in PBS with 0.1 % bovine serum albumin 
(BSA). A polyclonal rabbit anti-human IgG at relevant dilutions of 
anti-IL-4 and anti-IFN-y was used as a control antibody. 
Monocyte Stimulation Purified normalmonocytes were resus-
pended in GBSS at 2 X 106/ml and incubated at 37°C with T-cell 
supernatants, IL-4, or IFN-y for 1 to 72 h, as previously described 
[24) . For antibody neutralization, supernatants and cytokine-con-
taining buffers were incubated with either anti - IL-4 or anti - IFN-y 
for 1 hat 3rc prior to usage for monocyte treatment. After incu-
bation, cells were washed twice with cold GBSS andresuspended in 
GBSS at 107/ml. T-cell culture medium (RPMI-1640 plus 10% 
FCS plus 1% L-glutamine and 1 % streptomycin/penicillin) was 
used as control for T-cell supernatants stimulation assay, and 0.1 % 
BSA in PBS was used as control in cytokine stimulation assay. 
Cyclic AMP Phosphodiesterase Activity Monocytes at 107 
cells/ml in GBSS were thrice freeze/thawed in dry ice/ethanol, 
then sonicated at 4 ° C with a Branson Sonifier-250 for 2 min at 50 
watts. The homogenates were assayed for PDE activity using a 
modified procedure of Thompson et al [25) . The homogenated 
samples were mixed with equal volume of a substrate mixture con-
taining 1 .uM cAMP, 2 X 105 cpm [3H)-cAMP (New England Nu-
clear, Boston, MA), 80 mM Tris-HCI buffer (pH 8.0), 3.75 mM 
p-mercaptoethanol, and 40 mM MgCI2 . After 30 min incubation at 
30° C, the reaction was stopped by boiling for 60 seconds then 
snap-freezing in an ethanol/dry ice mixture. The reaction mixture 
was incubated subsequently with lOO.u1 of 5' -nucleotidase solution 
(1 mg/ml Cobra Venom, Sigma) for 10 min at 30 °C and then 
mixed with 1 ml of 200 - 400 mesh AG 1 X 2 ion exchange resin 
(Bio-Rad, Richmond , CA) for at least 30 min at 4 0e. After spinning 
(200 X g, 10 min at 4 ° e), the radioactivity in the supernatant was 
quantitated by a LS 3801 scintillation counter (Beckman, Fullerton, 
CA) and enzyme activity was expressed as pmol cAMP hydrolyzed 
per minute per microgram (.ug) protein. Each assay was standard-
ized with a purified bovine PDE (Sigma). We found the PDE activ-
ity varied less than 10% of the mean in each assay. 
Statistics Student t test and Mann-Whitney U test were used for 
analysis of data. A p value of less than 0.05 was considered to be 
significant. The data are expressed as mean ± SEM. 
RESULTS 
Effect ofIL-4 on Monocyte PDE Activity We first examined 
the effect of rhIL-4 on NL monocyte PDE activity. Incubation with 
rhIL-4, 0 to 100 units/ml, gave dose-related stimulation of PDE 
activity up to 50 units/ml (Fig 1a) . The maximal activation oc-
curred at 50 units/ml (n = 6, P = 0.017), whereas the minimal 
stimulatory dose was 0.005 units/ml. To show the specificity of this 
effect, normal monocytes were incubated with 10 units/ml of rhIL-
4 or rhlL-4 plus anti- IL-4 from 0.00025 to 0.025 .ug/ml for 60 min 
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Figure 1. a) Effect of rhIL-4 on normal monocyte POE activity. Monocytes 
Were treated with rhIL-4 at doses ranging from 0 units/ml to 100 units/ml 
or with 0.1 % BSA in PBS as control. Phosphodiesterase activity was ex-
pressed as mean percent increase over control ± SEM of the number of 
~Xperiments indicated on the graph. 100% is used as the control level. f < 0.05 , •• P < 0.01 compared to the control. b) Dose-dependent study 
o effect of anti _ IL-4 on IL-4 activation of normal monocyte POE. Normal 
I~Onocytes were incubated with 10 units/ml ofIL-4 or 10 units/ml ofIL-4 
pUs anti- 1l_4 from 0.00025 ,ug/ml to 0.025 ,u/ ml. 0.1 % BSA in PBS was 
used a I f ' 
. • s Contro . The values represent mean ± SEM 0 two experIments. 
p < 0.05 compared to the control. 
~\:5rc .. A.s shown in Fig Ib, rhIL-4, 10 units/ml , alone increased 
d ~ .actlvlty in normal monocytes by 109.85 ± 35.11 % , whereas ~L dltlon of anti-IL-4 caused a dose-dependent inhibitory effect on 
-/4 actIVation of monocyte PDE activity. For instance, at 0.00025 ~t rnl, anti-IL-4 inhibited the IL-4 effect by 49.51 ± 17 .69%. 
e.dose of anti-IL-4 (0.0025 Ilg/ml) used in this study h ad a ~e~h.glble inhibitory effect (3.54%) on IFN-y activation of PDE 
(~~~lty, whereas it inhibited the effect ofIL-4 by 79.66 ± 1.3.3~% 
t" Ie I). Rabbit anti-human IgG used as a control caused no 1l111lbl-
IOn of PDE activity. 
EI freet ofIFN_y on Monocyte POE Activity Previous reports 
lave d . . d I r' ernonstrated that IFN-y IS a macrophage activator an laS 
t eCIP
I 
rocal effects with IL-4 on other systems [8 ,26 - 28]. This led us 
o a so . I a: f .. 1'1 examl11e t l e eu ect 0 rhIFN-y on monocyte PDE activity. 
30~ ceHs Were incubated with rhIFN-y over a dose range from 0 to 
stud.unlts/ml at 37 °C for 1 h, which was shown in time-course 
obt ~es to give optimal effect. The baseline monocyte PDE activity, 
prn ained by incubation with 0 .1 % BSA in PBS, was 0 .54 ± 0 .07 
o /rnln/ Ilg protein. The rhIFN-y increased PDE activity signifi-
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candy, from 67.06 ± 14.74% at 0.005 units/ml to a peak of315 ± 
54.66% at 100 units/ml, in a dose-dependent fashion (Fig 2a). 
To confirm the stimulatory effect of IFN-y on monocyte PDE 
activity, 0.01 to 10 neutralization units (Nu)/ml of anti -IFN-y 
were applied in this study. As shown in Fig 2b, addition of anti -
IFN-y caused a dose-related inhibition of IFN-y activation of PDE 
in monocytes. Antibody specificity was shown by the fact that at 0.1 
units/ ml, anti- IFN -y caused 100% inhibition of IFN-y activation 
of monocyte PDE, w hereas it only inhibited effect ofIL-4 by 3.27% 
(Table I) . Rabbit anti- human IgG antibody used as control had no 
inhibitory effect on IFN-y-induced PDE activity. 
Effect of Normal and AO T-Cell Culture Supernatants on 
Monocyte POE Activity Because both IL-4 and IFN-y are the 
products of T cells, we next assessed whether increased cytokine 
secretion by activated T cells might be a cause for hi gh PDE activity 
in AD monocytes, we compared the effects of norm al and AD 
T-cell sups on normal monocytes. These cells were incubated for 60 
min with different dilutions ofT-ceil culture supernatants (1 : 2500, 
1 : 1000, 1 : 500, 1: 100 and 1: 4) fr0111 normal or AD donors. The 
basal PDE activity of normal monocytes (incubating monocytes 
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Figure 2. a) Effect of rhlFN-y on normal monocyte phosphodiesterase 
activity. Monocytes were incubated with either 0.1 % BSA in PBS as control 
or varying doses of rhIFN-y. Phosphodiesterase activity is expressed as mean 
percent increased over control ± SEM. The number of experiments are 
indicated on the graph . • p < 0.05, •• P < 0.005 compared to the control. 
b) Dose-dependent study of effect of anti - IFN-y on IFN-)' activation of 
normal monocyte POE. Normal monocytes were incubated with 10 units/ 
ml ofIFN-yor 10 units/ ml of IFN-)' plus anti- IFN-y from O.Olu/ ml to 10 
u/ ml. 0.1 % BSA in PBS was used as control. The values represent mean ± 
SEM of two experiments. • p < 0.05 compared to the control. 
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Table I. Antibody Inhibition of T-Cell Supernatant, IL-4, and 
IFN-y Effect on Monocyte Phosphodiesterase Activity' 
Percent Inhibition 
of Monocyte POE Activity 
Monocyte POE Stimuli Anti-IL-4b Anti-IFN-yb 
1) Normal T-cell supernatants 75.94 ± 3.56 86.21 ± 19.51 
2) ADT cell supernatants 97.83 ± 3.08 55.5 ± 1.7 
3) rhIL-4 79.66 ± 13.34 3.27 
4) rhIFN-y 3.54 100 ± 30.15 
• Normal monocytes were incubated with T-cell supernatants, IL-4 and IFN-yalone, 
or these cytokines plus anti - IL-4 (0.0025/-lg/ml) or anti - IFN-y (0.1 neutralization 
units/ml). POE activity (pmol/min/ /-lg protein) induced by 1) normal T-cell superna-
tants (1: 20) increased by 80.79 ± 36.85 (mean ± SEM, n = 2); 2) AD T-cell superna-
tants (1 : 20) by 94.59 ± 22.92 (mean ± SEM, n = 2); 3) rhIL-4 (10 units/ml) by 
109.85 ± 35.11 % (mean ± SEM, n = 3), and 4) rhIFN-y (10 units/ml) by 69.52 ± 
1.8% (mean ± SEN , n = 2). 
bpercent inhibition 
= stimulus alone - (stimulus + anti-IL-4 or anti - IFN-Y) X OODA 
stimulus alone - baseline 1 D. 
with RPMI-1640 supplemented with 10% FCS and 1 % L-gluta-
mine, 1 % streptomycin/penicillin) was 0.6 ± 0.13 (mean ± SEM, 
n = 9) pmol/min/,ug protein. Figure 3 shows that both AD and 
normal T-cell supernatants caused a dose-related increase in normal 
monocyte POE activity compared to the baseline POE activity of 
monocytes. For instance, AD T-cell supernatants increased mono-
cyte POE activity from 34% (at 1: 2500) to 390% (at 1: 4) and 
normal T-cell supernatant increased monocyte POE activity from 
15% (at 1 : 2500) to 330% (at 1: 4). At concentrations of T-cell 
supernatant greater than 1: 1000 dilution, both AD and normal 
supernatant significantly increased POE activity above the control 
levels (p < 0.05) . . 
Although supernatant from AD T -cell cultures appeared to have a 
greater effect on monocyte POE activity compared to supernatant 
fro m normal T-cell cultures , there was no significant difference 
between the two groups (p = 0.58). The analysis clearly showed 
that the sporadic high levels of POE activity were due to randomly 
high responses of monocytes and were quite independent ofT-cell 
supernatants. In time-course study, we incubated normal monocytes 
with normal or AD T-cell culture supernatants for 60 min, 1 h, and 
48 h. There was no difference between the effect of NL and AD 
T-cell sups at any of the time points. Maximal stimulation occurred 
at 60 min. 
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Figure 3. Effect of T-cell supernatants on normal (NL) monocyte POE 
activity. Monocytes were treated with varying dilutions of normal (black 
bars) or AD T-cell supernatants (Sups) (shaded bars). The control levels of 
POE activity (0.6 ± 0.13, n = 9) were obtained by incubating monocytes 
with T-cell culture medium (RPMI-1640) supplemented with 10% FeS, 
1 % L-glutamine, and 1 % streptomycin/penicillin). POE activity is ex-
pressed as mean percent increase over control values ± SEM .• P < 0.05 
compared to control. 
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Antibody Neutralization of the T-Cell Supernatant 
Effect Because both recombinant IL-4 and IFN-y had stimula-
tory effects on normal monocyte POE activity, we assessed whether 
IL-4 or IFN-y were involved in the elevated POE activity after 
stimulation by T -cell supernatants. 0.0025 ,ug/ml of anti - IL-4 and 
0.1 Nu/ml of anti - IFN-y were used to neutralize the effect of AD 
or NL T-cell supernatants. As shown in Table I, at 1: 20 dilution, 
normal T -cell supernatants alone increased monocyte POE activity 
by 80.79 ± 36.85% and AD T-cell supernatants increased POE ac-
tivity in normal monocytes by 94.59 ± 22.92%. Anti-IL-4, at 
0.0025 ,ug/ml, inhibited the effect of AD T-cell supernatants by 
97.83 ± 3.08% and the effect of normal T-cell supernatants by 
75.49 ± 3.56%. 0.1 Nu/ml of anti-IFN-y reduced the effect of 
AD T-cell supernatants on normal monocyte POE activity by 
55 .5 ± 1.7% and the effect of normal T-cell supernatants by 
86.21 ± 19.51 %. These results suggest th at both IL-4 and IFN-y 
are involved in the T-cell supernatant activation of normal mono-
cytes POE. 
Effect of Combined IL-4 and IFN-y on Normal Monocyte 
PDE Activity We next studied the effect of combining IL-4 and 
IFN-y on normal monocyte POE activity. Incubation of monocytes 
with 0.001 to 1 unit of combined IL-4 and IFN-y showed a dose-de-
pendent effect on POE activity (data not shown). The maximal 
synergistic effect occurred at 0.1 units/m!. We chose the subopti-
mal combination of 0.005 units/ml IL-4 and IFN-y to perform 
further experiments. Table II shows that, at 0.005 units/ml, IL-4 or 
IFN-y alone significantly increased POE activity in monocytes by 
65 .16 ± 16.81 % and 67.06 ± 14.74%, respectively (p < 0.05). 
The combination ofIL-4 and IFN-y caused statistically greater stim-
ulatory effect on monocyte POE activity than either IL-4 or IFN-y 
alone (p < 0.05), and this increase (225.75 ± 34.18%) showed a 
synergistic effect of IL-4 and IFN-y These results indicated that, at 
very low doses, IL-4 and IFN-y have a synergistic effect on mono-
cyte POE activity and this is in agreement with the previous finding 
that IL-4 and IFN-y synergistically activate human monocytes and 
Langerhans' cells [29,30]. 
Phosphodiesterase Characterization Monocyte cAMP-POE 
is a low Km POE as shown by our previous studies [4]. To character-
ize the POE form activated by cytokines, we determined the Km of 
NL monocyte POE before or after stimulation. Results (Table III) 
indicate that IFN-y and IL-4 activated a POE form with Km identi-
cal to that present in unstimulated control monocytes . 
DISCUSSION 
In this study we showed that both IL-4 and IFN-y have stimulatory 
effects on normal monocyte POE activity and that these effects are 
synergistic with combined IL-4 and IFN-y. These results demon-
strated that the effects of IL-4 and IFN-y on cyclic nucleotides, 
particularly combination of both cytokines, occurred well beloW 
levels detectable with currently available immunoassays. Our find-
ing of significant POE activation by concentrations of 0.005 units/ 
ml of lL-4 and lower might reflect a system in which only a few 
receptors need be occupied to stimulate a response . 
Antibodies against lL-4 and IFN -y blocked the cytokine effects of 
IL-4 and IFN-y, respectively. These results suggest a mechanism by 
which IL-4 and IFN-y may modulate immune function by stimulat-
ing monocyte POE activity and, in turn, modulate cellular cyclic 
nucleotide metabolism. IL-4 has pleiotropic effects on mononuclear 
cells, including co-stimulation of B-cell proliferation, IgE isotype 
switch [31), induction of CD23 expression on Langerhans' cells, 
monocytes and B lymphocytes [29,32,33]; and inhibition ofT-cell 
IFN -y production at the mRNA transcription level [10,11]. It has 
been reported that IFN-y also exerts various effects on monocytes, 
such as expression of class II major histocompatibility complex ceJl-
surface antigen, synthesis of tumor necrosis factor-alpha (TNF-a) 
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Table II. Effect of the Combination of IL-4 and IFN-y o n Normal Monocyte POE Activity· 
Experiment 1 Experiment 2 Experiment 3 Mean ± SEM P Valueb P Value' 
1. Contro l 0 .81 1.22 0.85 0.96 ± 0.13 
2. IL-4 1.58 1.67 1.39 1.55 ± 0.08 0.034 0.039 
3. IFN-y 1.22 1.88 1.67 1.59 ± 0.20 0.043 0.011 ~ IL-4 + IFN-y 2.58 3.30 3.30 3.06 ± 0.24 0.017 
• Normal monocytes were incubated with 0.005 units/ml of IL-4, 0.005 units/ml of IFN-y, or the combination of both cytokines for 1 hat 37'C. POE activity was expressed as 
p~oljmlll/Jig protein. The control consists of 0.1 % BSA in PBS. . . 
The p values were obtai ned by comparing the means of IL-4, IFN-y, or the comb matI on of IL-4 and IFN-y to the mean of control POE activity. 
' The p values were from comparing the mean of IL-4 or IFN-y with the mean of IL-4 plus IFN-y. 
and IL-2 receptor, and inhibition of m o nocyte migration [26 - 28]. 
IFN-'y, while antagoniz ing som e IL-4 effects on B cells, exerts simi-
lar bIologic effec ts to IL-4 on monocytes and Langerhans' cells 
[29,30,34] . The fac t that very low levels ofIL-4 and IFN-y alone or 
synerg istically stimulate monocyte POE activity provides a possible 
mechanism of immune and inflammatory regulation that may relate 
to many of these biologic effects. 
Supernatants of T cells from either normal or AD subjects also 
produced stimulatory effects similar to the cytokine effects on nor-
mal monocyte POE activity . Because antibodies against IL-4 and I~N-y inhibited the effects of T cell supernatants, these two cyto-
kmes appear to be ac tive agents involved in T-cell regulation of 
monocyte POE activity. Present techniques are not sensitive 
enough to de tec t the level of these cytokines in the T-cell superna-
tants, though it seem s that IL-4 and IFN-y act at very low levels for 
actIvation o f monocyte POE. This has been confirmed by the ex-
penments showin g tha t the low concentration of IL-4 and IFN-y 
(?elow the ELISA detectable levels, 2.25 and 2.5 units/ ml , respec-
tIvely) could sig nificantly and synergistically stimulate POE activ-
Ity of monocytes. The actual levels of the cytokines in the T-cell 
Supernatants m ay be so low that they require a mutually d ependent 
synergIstic interaction to stimul ate the monocyte POE. Inhibiting 
eaher cytokine greatly reduced the effects ofT-cell supernatants on 
monocyte POE activity. 
Recent information suggests that atopic T cells produce relatively 
~reater amounts of IL-4 in comparison to IFN-y [19,35,36] . Our 
ata (Table I) showed that anti - IL-4 had a greate r inhibitory effect hn AD T-cell supernatants than anti - IFN-y, whereas anti-IFN-y 
ad a lesser effect and this m ay reflect a relatively greater IL-4 
concentration in the atopic T-cel l cultures. These results furthe r 
support the evidence that IL-4 and IFN-y are disproportionately 
produced by AD compared to normal T cells. 
?ur enzyme kinetics results showed that IL-4 or IFN-y appar-
eht y stimulated POE activity by a similar m echanism, without ~~ngmg the Km of the enzyme but increasing the Vmax of the 
· E. These results, combined with the fact that activation occurs ~thin 60 min, su ggest that activation of normal monocyte POE by 
I -4 and IFN-y m ay be through post-translational modulation of ~ l e e nzyme [24] . The evidence that IL-4 and IFN-y, at low concen-
ratIons, have synergistic effects a lthough the concentrations 
greate~ than 0 .1 units/ml IL-4 plus IFN-y showed no further in-
crease In monocyte POE activation, indicates saturation. This sug-
Table III 
------= . Km of Normal Monocyte cAMP-Phosphodiesterase· 
----
Control rhIL-4 rhINF-y 
PDE' 0.38 ± 0.06' 0.79 ± 0.12d 1.5 ± 0.3d I<rn' 
---
1 1.3 1.33 
Un; t~orlal monocytes were treated with either 0.1 % BSA in PBS as control, 10 
• PD~ ofrhIL_4. or 10 units/ml of rhIFN-y. 
' TI ac tIvIty IS expressed as pmoljmin/Jig protein. 
J p ~ ~alues of POE activity are mean ± SEM of four experiments. 
, Ie .01 (as compared with the control). 
tratio m art obtained by Lineweaver-Burk double reciprocal plot with different concen-substr~St 0 cAMP (0.1 JiM , 0.125 JiM, 0.211M, 0.5 JiM , I JiM, 2 JiM, and 10 JiM) as the 
e. 
ges ts that IL-4 and IFN -y m ay act on different receptors or target 
proteins coupling to a common m echanism that modulates cyclic 
nucleotide m etabolism. 
Though we predicted that AD T-cell supernatants might cause a 
greater stimulatory effect on n o rmal monocyte POE activity, we 
found no statistical evidence for this when comparing the effects of 
normal and AD T-cell supernatants on normal m o nocyte POE activ-
ity. Thus, we cannot invoke this m ech anism to account for elevated 
monocyte POE activity in patients with atopic dermatitis [1 ,4]. 
This study h as demonstrated for the first time that cytokines su ch 
as IL-4 and IFN-y can modulate monocyte POE activi ty. This pro-
vides a m ech anism fo r immunologic interaction w ith the cyclic 
nucleotide regulatory sys tem in leukocytes. These results m ay help 
clarify the cellular functional effects of cytokines, not only in mon-
ocytes, but in a variety of cell s that are under cyclic nucleotide 
control. 
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